These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26868617)

  • 21. Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism.
    De Graaf IA; Van Meijeren CE; Pektaş F; Koster HJ
    Drug Metab Dispos; 2002 Oct; 30(10):1129-36. PubMed ID: 12228190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection.
    Yu C; Chen CL; Gorycki FL; Neiss TG
    Rapid Commun Mass Spectrom; 2007; 21(4):497-502. PubMed ID: 17221928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
    Hutzler JM; Yang YS; Albaugh D; Fullenwider CL; Schmenk J; Fisher MB
    Drug Metab Dispos; 2012 Feb; 40(2):267-75. PubMed ID: 22031625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro species comparisons and metabolite identification.
    Dow P
    Curr Protoc Pharmacol; 2006 Oct; Chapter 7():Unit7.10. PubMed ID: 22294177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH; Bouchene S; Hilgendorf C; Dolgos H; Peters SA
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
    Prakash C; Li Z; Orlandi C; Klunk L
    Drug Metab Dispos; 2012 Jul; 40(7):1308-20. PubMed ID: 22474055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of cryopreserved hepatocytes as an alternative to fresh hepatocytes for comparative interspecies metabolism studies with suitable acceptance criteria.
    Cheng ZZ; Herron CE; Bowers G; de Serres M
    Drug Metab Lett; 2007 Apr; 1(2):109-20. PubMed ID: 19356029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting circulating human metabolites: how good are we?
    Anderson S; Luffer-Atlas D; Knadler MP
    Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
    Jones RD; Jones HM; Rowland M; Gibson CR; Yates JW; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4074-89. PubMed ID: 21452299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
    Obach RS; Nedderman AN; Smith DA
    Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Model-based drug discovery: implementation and impact.
    Visser SA; Aurell M; Jones RD; Schuck VJ; Egnell AC; Peters SA; Brynne L; Yates JW; Jansson-Löfmark R; Tan B; Cooke M; Barry ST; Hughes A; Bredberg U
    Drug Discov Today; 2013 Aug; 18(15-16):764-75. PubMed ID: 23726890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.
    Uusitalo J; Turpeinen M; Tolonen A; Koskimies P; Lammintausta R; Pelkonen O
    Drug Metab Pers Ther; 2016 Mar; 31(1):35-40. PubMed ID: 26581074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
    Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
    Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.